PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18376358-0	2008	Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?	Rosiglitazone	0-13	potassium voltage-gated channel interacting protein 3	Homo sapiens	72-77	
21116607-1	2011	AIMS/HYPOTHESIS: The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%.	Rosiglitazone	69-82	potassium voltage-gated channel interacting protein 3	Homo sapiens	95-100	
21116607-1	2011	AIMS/HYPOTHESIS: The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%.	Rosiglitazone	146-159	potassium voltage-gated channel interacting protein 3	Homo sapiens	95-100	
20628086-0	2010	Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.	Rosiglitazone	139-152	potassium voltage-gated channel interacting protein 3	Homo sapiens	165-170	
18376358-1	2008	Results of the recently published DREAM trial seemingly demonstrate that the PPAR-gamma agonist rosiglitazone is effective in the prevention of diabetes.	Rosiglitazone	96-109	potassium voltage-gated channel interacting protein 3	Homo sapiens	34-39	
18035959-14	2007	More recently, the DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) study (n = 5269) demonstrated that rosiglitazone at 8 mg once/day in subjects with prediabetes (IGT and/or impaired fasting glucose) was effective in reducing the risk of diabetes by 60%.	Rosiglitazone	135-148	potassium voltage-gated channel interacting protein 3	Homo sapiens	19-24	
12324991-10	2002	The possibility that ACE inhibitor treatment with ramipril may prevent new diabetes in non-diabetic patients at high risk of the disease is to be examined prospectively in the Diabetes Reduction Assessment with ramipril and rosiglitazone (DREAM) trial.	Rosiglitazone	224-237	potassium voltage-gated channel interacting protein 3	Homo sapiens	239-244	
19804301-0	2007	Rosiglitazone: a disappointing DREAM.	Rosiglitazone	0-13	potassium voltage-gated channel interacting protein 3	Homo sapiens	31-36	
17684471-0	2007	Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.	Rosiglitazone	124-137	potassium voltage-gated channel interacting protein 3	Homo sapiens	150-155	
17354538-2	2007	It is the DREAM study which evaluate the therapeutic effects of rosiglitazone and ramipril versus placebo in the prevention of type 2 diabetes in high risk patients: glucose intolerance or impaired fasting glucose.	Rosiglitazone	64-77	potassium voltage-gated channel interacting protein 3	Homo sapiens	10-15	
17209507-0	2006	[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].	Rosiglitazone	65-78	potassium voltage-gated channel interacting protein 3	Homo sapiens	1-6	
15628822-6	2004	Prospective studies such as Diabetes REduction Approaches with ramipril and rosiglitazone Medications (DREAM) are currently evaluating the long-term effects of thiazolidinediones on metabolic status and disease progression.	Rosiglitazone	76-89	potassium voltage-gated channel interacting protein 3	Homo sapiens	103-108	
15322749-13	2004	CONCLUSIONS/INTERPRETATION: The DREAM trial and related studies will determine if ramipril or rosiglitazone reduces the number of cases of diabetes and atherosclerosis, and will identify novel risk factors for diabetes.	Rosiglitazone	94-107	potassium voltage-gated channel interacting protein 3	Homo sapiens	32-37